TD Asset Management Inc grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) by 16.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,199 shares of the biopharmaceutical company’s stock after acquiring an additional 9,400 shares during the period. TD Asset Management Inc owned about 0.12% of Agios Pharmaceuticals worth $1,831,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Signaturefd LLC boosted its holdings in shares of Agios Pharmaceuticals by 92.5% in the third quarter. Signaturefd LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 482 shares during the period. Point72 Hong Kong Ltd purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $39,000. Lazard Asset Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 37.9% in the first quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 805 shares during the period. Inspire Investing LLC purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $206,000. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $213,000.
Agios Pharmaceuticals Price Performance
NASDAQ AGIO opened at $25.41 on Tuesday. The stock’s fifty day moving average price is $22.89 and its 200 day moving average price is $26.51. Agios Pharmaceuticals, Inc. has a 1 year low of $16.75 and a 1 year high of $34.76. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -6.40 and a beta of 0.96.
Insiders Place Their Bets
In other Agios Pharmaceuticals news, Director David P. Schenkein sold 20,000 shares of the stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $22.49, for a total transaction of $449,800.00. Following the sale, the director now directly owns 117,879 shares of the company’s stock, valued at approximately $2,651,098.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Agios Pharmaceuticals news, Director David P. Schenkein sold 20,000 shares of the stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $22.49, for a total transaction of $449,800.00. Following the sale, the director now directly owns 117,879 shares of the company’s stock, valued at approximately $2,651,098.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David P. Schenkein sold 16,363 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $22.85, for a total value of $373,894.55. Following the sale, the director now directly owns 117,879 shares in the company, valued at $2,693,535.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 77,100 shares of company stock valued at $1,857,677. Company insiders own 4.48% of the company’s stock.
Analysts Set New Price Targets
A number of analysts recently issued reports on AGIO shares. Piper Jaffray Companies started coverage on Agios Pharmaceuticals in a report on Friday, February 3rd. They issued an “overweight” rating and a $41.00 price target for the company. Piper Sandler assumed coverage on Agios Pharmaceuticals in a report on Friday, February 3rd. They set an “overweight” rating and a $41.00 target price for the company. SVB Securities lowered their target price on Agios Pharmaceuticals from $37.00 to $34.00 in a report on Friday. Finally, StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $37.00.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Articles
- Get a free copy of the StockNews.com research report on Agios Pharmaceuticals (AGIO)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
